Related references
Note: Only part of the references are listed.BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome
Christopher W. Toon et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Paul Lochhead et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers
Simon K. Chan et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
HER2, TOP2A, CCND1, EGFR and c-MYC oncogene amplification in colorectal cancer
Khawla Al-Kuraya et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Share Paper
